Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
via Google News
The Latest on: Heroin vaccine
- Queried cattle vaccine genuine, says UK labon September 7, 2019 at 3:16 am
If the cold chain breaks the drug may be ineffective. The third issue is whether the animals that were vaccinated had been exposed to chemicals and antibiotics.” This can make the vaccine ineffective.
- HIV prevention is making progress. And a breakthrough vaccine appears within reachon September 6, 2019 at 6:08 am
and urge them to take that drug in lieu of joining the study. Only those who say they still want to forgo the treatment will be able to participate. Other trials are already underway. In sub-Saharan ...
- The Chinese Human Vaccine Industry: 2019-2025 Analysis & Outlook Report - ResearchAndMarkets.comon September 4, 2019 at 5:09 pm
The National Institutes for Food and Drug Control approved supply of 276.6 million doses (37 kinds of vaccines) to the market from January to July 2019. Thereof, China National Biotech Group ...
- Critics ‘alarmed by lack of interest’ in studying children put at risk by dengue vaccineon September 4, 2019 at 9:01 am
“We rushed it then, and the vaccine is of no use for the current outbreak,” Dans says. “Let’s take our time.” Dengvaxia can still potentially benefit a carefully chosen population. That’s why the U.S.
- Brucella Abortus Vaccine Market Size and Forecast 2026 | SWOT Analysis, Key Insights and Company Profileson September 4, 2019 at 7:47 am
The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Brucella Abortus Vaccine market.
- Visiongain Report Looks at Opportunities within the $75bn Vaccines Sales Marketon September 4, 2019 at 2:11 am
Developing Countries Vaccine Manufacturers Network (DCVMN)European Medicines Agency (EMA) Federation of Pharmaceutical Manufacturers & Associations (IFPMA)Food and Drug Administration (FDA) Global ...
- Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpileon September 3, 2019 at 7:26 pm
ACAM2000 vaccine is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) for active immunization against smallpox disease for persons determined to be at high risk for smallpox ...
- Doctors Without Borders criticizes the Gavi coalition over access to pneumonia vaccineson September 3, 2019 at 12:23 pm
At issue is the cost of pneumococcal vaccines that Gavi helps countries purchase through a financing mechanism. Created nearly two decades ago, Gavi is a public-private partnership that acts as a ...
- Emergent lands federal contract for smallpox vaccine potentially worth more than $2Bon September 3, 2019 at 11:28 am
The vaccine, known as ACAM2000, is the only preventative option approved by the Food and Drug Administration for patients deemed at high risk of infection from smallpox. The Gaithersburg company first ...
- Targeting flesh-eating, drug-resistant bacteria, Peninsula company grabs small grant for antibioticon September 3, 2019 at 8:32 am
In the grand scheme of drug development, $1.6 million isn't much, but for a small Peninsula vaccines developer — and people with a common and potentially deadly bacterial infection — it could mean the ...
via Bing News